Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
November 2, 2026
5 min read
Early characterization and manufacturing planning can help developers choose the right formulation strategy for complex oral therapies
October 30, 2026
5 min read
Erik Vaessen on the costs, complexities, and technologies shaping advanced therapy manufacturing.
October 22, 2026
5 min read
Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner
October 7, 2026
1 min read
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization